Core Insights - The increasing prevalence of gout and hyperuricemia in China presents a significant market opportunity for innovative treatments, with approximately 221 million hyperuricemia patients and 25.3 million gout patients projected for 2024 [2][13]. - New Element Pharmaceuticals, a company focused on gout treatment, is seeking to go public in Hong Kong, facing competition from established firms like Hengrui Medicine and Kanyuan Pharmaceutical [3][16]. Company Overview - New Element Pharmaceuticals was founded in 2012 and has undergone five rounds of financing, raising approximately 1.078 billion RMB, with a current valuation of about 3 billion RMB [4][6]. - The company is led by Dr. Shi Dongfang, who has extensive experience in drug development and holds a significant stake in the company [8][4]. Product Pipeline - The company is developing two clinical-stage products, ABP-671 and ABP-745, targeting gout and hyperuricemia, along with several preclinical candidates [16][26]. - ABP-671 is a URAT1 inhibitor currently in phase 2b/3 clinical trials in the US and China, showing promise as a first-line treatment for gout [18][20]. Financial Performance - New Element Pharmaceuticals has reported significant losses over the past two and a half years, totaling 696 million RMB, with no products approved for commercial sale yet [29][31]. - The company's R&D expenses have been substantial, accounting for over 90% of total operating expenses, indicating a strong focus on developing its drug pipeline [32][33]. Market Landscape - The global market for hyperuricemia and gout treatments is estimated at approximately 3.2 billion USD, with a growing need for safer and more effective therapies [12][20]. - The competitive landscape includes multiple established pharmaceutical companies and over 100 generic drugs approved for treating hyperuricemia and gout, highlighting the challenges New Element Pharmaceuticals faces [20][22][23].

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The adjustment of medical insurance and commercial insurance directories is accelerating, suggesting a favorable environment for undervalued quality stocks during market corrections [4][5] - The report emphasizes the importance of timing and stock selection in the current market, particularly after a broad rally in innovative drug stocks [4] - The upcoming ESMO conference in October is highlighted as a key event, with specific companies recommended for attention due to potential significant data releases [4] Summary by Sections Market Performance - The Hang Seng Index fell by 1.1% and the Hang Seng Healthcare Index decreased by 1.4% during the week of September 16-23, 2025, ranking 5th among 12 industry indices [4][6] - Sub-industry performance varied, with Internet medicine showing a slight increase of 0.9%, while sectors like medical devices and hospitals saw declines of 5.2% and 8.2%, respectively [4][6] Valuation Overview - The report provides a detailed valuation summary for various companies, with notable price-to-earnings (P/E) ratios for the pharmaceutical sector, such as 31.0x for prescription drugs and 14.1x for biopharmaceuticals [15] - The average P/E ratio across the sector is reported at 57.0, indicating a diverse valuation landscape [3] Institutional Holdings - As of September 23, 2025, domestic institutional holdings through Hong Kong Stock Connect remained stable at 22.2%, while foreign holdings slightly decreased to 38.7% [34][38] - The report notes a trend of increased foreign investment in innovative drug companies, with specific companies like InnoCare and Legend Biotech seeing significant increases in holdings [38][40] Regulatory Developments - The report discusses the recent adjustments to the national basic medical insurance directory and commercial insurance innovative drug directory, with a low approval rate for submitted drugs [5] - The 11th batch of national drug procurement has been announced, with new rules aimed at stabilizing clinical practices and ensuring quality [5]

Core Viewpoint - Tonghua Dongbao's stock price has shown a modest increase of 6.12% year-to-date, with recent fluctuations indicating a slight decline over the past 20 days and a small gain over the last 60 days [1] Group 1: Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. is located in Tonghua County, Jilin Province, and was established on December 28, 1992, with its listing date on August 24, 1994 [1] - The company's main business includes hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biological engineering products (recombinant human insulin injection) [1] - The revenue composition of the company is as follows: biological products (raw materials and formulations) 90.29%, medical devices such as injection pens and blood glucose test strips 6.07%, traditional Chinese medicine and chemical drugs 2.24%, and others 1.27% [1] Group 2: Financial Performance - For the first half of 2025, Tonghua Dongbao achieved an operating income of 1.373 billion yuan, representing a year-on-year growth of 85.60%, and a net profit attributable to shareholders of 218 million yuan, reflecting a year-on-year increase of 194.48% [2] - The company has cumulatively distributed dividends of 5.509 billion yuan since its A-share listing, with 1.973 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders of Tonghua Dongbao was 86,500, a decrease of 7.02% compared to the previous period, with an average of 22,632 circulating shares per shareholder, an increase of 7.55% [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., Ltd. and Hong Kong Central Clearing Limited, with varying changes in their holdings compared to the previous period [3]

Core Viewpoint - The announcement details the share pledge and unpledging activities of Tonghua Dongbao Pharmaceutical Co., Ltd.'s controlling shareholder, Dongbao Industrial Group Co., Ltd., indicating a high level of share pledging and its implications for the company's financial health and governance [1][2][3]. Group 1: Shareholding and Pledge Details - Dongbao Group and its concerted parties hold a total of 634,511,775 shares, accounting for 32.40% of the company's total shares [1]. - After the recent unpledging and re-pledging, the total number of pledged shares is 565,939,472, which represents 89.19% of the shares held by Dongbao Group and its concerted parties, and 28.90% of the company's total shares [1][2]. - Dongbao Group holds 612,649,596 shares, which is 31.28% of the total shares, with 565,939,472 shares pledged, equating to 92.38% of its holdings [1][2]. Group 2: Financial Implications and Debt Management - On September 22, 2025, Dongbao Group unpledged 14,000,000 shares and subsequently pledged the same number of shares to China Construction Bank for debt repayment purposes [2][3]. - The total number of shares due for pledge expiration in the next six months is 81,000,000, representing 13.22% of its holdings and 4.14% of the company's total shares, with a corresponding financing balance of 31.5 million [3]. - For the next year, 191,350,000 shares are set to expire, which is 31.23% of its holdings and 9.77% of the company's total shares, with a financing balance of 96.5 million [3]. Group 3: Impact on Company Operations and Governance - The share pledging activities are not expected to impact the company's operations or governance, nor will they lead to a change in actual control [3][4]. - Dongbao Group has no performance compensation obligations that could be affected by the share pledging [3][4]. Group 4: Financial Health and Risk Assessment - Dongbao Group's financial health shows a relatively high debt-to-asset ratio and low liquidity ratios, which may pose challenges for debt repayment [9]. - The group plans to enhance operational efficiency, accelerate the conversion of research results, and manage share pledging ratios to mitigate risks associated with high share pledging [9][10].

Group 1 - Dongbao Group has completed the pledge release of 14 million unrestricted circulating shares to China Construction Bank on September 22, 2025 [1] - Dongbao Group and its concerted actions hold approximately 635 million shares, accounting for 32.4% of the total shares [1] - The total number of pledged shares by Dongbao Group and its concerted actions is about 566 million shares, representing 89.19% of their total holdings and 28.9% of the company's total shares [1] Group 2 - Dongbao Group holds approximately 613 million shares, which is 31.28% of the total shares [1] - The cumulative pledged shares by Dongbao Group amount to 566 million, making up 92.38% of their holdings and 28.9% of the company's total shares [1]

证券代码：600867 证券简称：通化东宝 公告编号：2025-059 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 634,511,775 股，占公司目前股份总额的 32.40%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 565,939,472 股，占 其及一致行动人所持有公司股份总额的 89.19%，占公司目前股份总额的 28.90%。 其中：东宝集团持有公司股份 612,649,596 股，占公司目前股份总额的 31.28%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 565,939,472 股， 占其所持有公司股份总额的 92.38%，占公司目前股份总额的 28.90%。 2025 年 9 月 23 日,本公司接到东宝集团关于股份解押及再质押相关情况 ...

Group 1 - The core viewpoint of the announcement is the successful passing of three key resolutions related to the employee stock ownership plan at the company's second extraordinary general meeting of 2025 [1][4][5] - The meeting was held on September 18, 2025, at the company's conference room, with all board members and supervisors present [2][3] - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2] Group 2 - The resolutions passed include the draft of the 2025 employee stock ownership plan, the management measures for the plan, and the authorization for the board to handle related matters [4][5] - The meeting was witnessed by Jilin Bingze Law Firm, confirming that the procedures and voting results were in accordance with legal and regulatory requirements [5]

通化东宝药业股份有限公司 2025 年员工持股计划 通化东宝药业股份有限公司 2025 年员工持股计划 证券代码：600867 证券简称：通化东宝 二〇二五年九月 0 通化东宝药业股份有限公司 2025 年员工持股计划 声 明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 1 通化东宝药业股份有限公司 2025 年员工持股计划 风险提示 一、通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"）2025 年员 工持股计划（以下简称"本员工持股计划"）的参与对象、资金来源、出资金额和具 体实施方案等属初步结果，能否完成实施，存在不确定性。 二、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低，本员 工持股计划存在无法成立的风险；若员工认购份额不足，本员工持股计划存在低于预 计规模的风险。 三、股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形势及投资者 心理等多种复杂因素影响。因此，股票交易是有一定风险的投资活动，投资者对此应 有充分准备。 三、本员工持股计划由公司自行管理，公司成立员工持股计划管 ...

吉林秉责律师事务所 关于通化东宝药业股份有限公司 二 0 二五年第二次临时股东会的法律意见书 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共和国公 司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规则》） 和《通化东宝药业股份有限公司章程》（以下简称《公司章程》）的有关规定，吉 林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股份有限公司（以 下简称"公司"）的委托，担任公司 2025 年第二次临时股东会（以下简称"本次 股东会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东会的公告材料，随其他需要公告 的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、商家碧律师出席了公司于 2025 年 9 月 18 日上午 10 时在公司会议室召开的本次股东会，审查了公司提供的与召开 本次股东会有关的文件和资料，并进行了验证。在此基础上，本所按照律师行业 公认的业务标准、道德规范和勤勉尽责的精神发 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-058 通化东宝药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 18 日 (二)股东会召开的地点：公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 657 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 245,727,014 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 18.7651 | | 份总数的比例（%） | | 审议结果：通过 表决情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | ...